Dr. Mia talks about the newly released preliminary results of anti-amyloid drug: lecanemab, the context of this newest drug development, and more questions than answers going forward.

News release of clinical trial Clarity AD (lecanemab) trial results
Biogen & Eisai's 50/50 relationship for lecanemab
Other trials including lecanemab
Biogen's recent $900 million lawsuit settlement due to improper physician payment
ARIA (Amyloid-related Imaging Abnormality): key side effects in lecanemab

Transcript & more at www.miayangmd.com
*Disclaimer: views expressed are Dr. Mia Yang's solely and do not represent her employer, National Institute of Health (NIH), or Patient-Centered Outcomes Research Institute (PCORI). Dr. Mia has no pharmaceutical company funding. 

Music & disclaimer